Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apitoxin, commonly known as honey bee venom, is a complex biological mixture containing peptides (such as melittin and apamin), enzymes (like phospholipase A2), and biogenic amines. In a clinical study led by Tanta University, a 0.3% apitoxin gel was evaluated for the treatment of recurrent aphthous stomatitis (RAS). The drug exerts its therapeutic effects through potent anti-inflammatory, analgesic, and wound-healing properties. It works by modulating the production of pro-inflammatory cytokines and providing a protective barrier over the ulcerated mucosa, thereby reducing pain and accelerating the resolution of aphthous ulcers. The study specifically compared the efficacy of this topical gel against low-level laser therapy (LLLT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Apitoxin.